A synthetic tetrapeptide studied for telomerase activation and potential lifespan extension — based on Khavinson's pineal research.
Epithalon (Ala-Glu-Asp-Gly, or AEDG) is a synthetic tetrapeptide developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a synthetic version of the natural pineal gland peptide epithalamin (polypeptide bovine pineal extract). The pineal gland produces hormones (melatonin) and peptides that regulate circadian rhythms and are linked to aging.
The primary interest in Epithalon stems from its proposed ability to activate telomerase — the enzyme that elongates telomeres (protective caps on chromosomes that shorten with each cell division). Telomere shortening is a hallmark of cellular aging, and restoring telomerase activity is a theoretical anti-aging mechanism. Epithalon is claimed to be one of the few compounds with demonstrated telomerase-activating properties.
Dr. Khavinson's group has published extensively on Epithalon and related Khavinson peptides (bioregulator peptides). While prolific, most of this research comes from a single institution and has not been independently replicated in large Western trials. The research includes both animal lifespan studies and limited human studies over decades.
Animal studies demonstrated lifespan extension in various models (mice, Drosophila). Reduction in oncogenesis (tumor formation) was observed. Improved immune function and antioxidant markers in aging animals. Human studies in elderly patients showed improvements in melatonin levels, sleep quality, and some health parameters.
Telomerase activation has been demonstrated in in vitro studies with human cells. Whether this translates to meaningful lifespan extension or cancer risk modification in humans requires much larger clinical validation than currently exists.
📚 Key Reference: PMID: 14552947 (Epithalon aging study), PMID: 21352908 (telomerase activation)
Epithalon has a favorable preclinical safety profile and has been used in Russian longevity research without major adverse events. Short-term human exposure data suggests tolerability. Long-term safety and potential pro-cancer risks from telomerase activation in somatic cells require careful consideration. Consult your provider.
NOT FDA-approved. Research use only. Available through compounding pharmacies. Primary research base is Russian — limited Western replication. One of the most popular but least rigorously validated longevity peptides by Western standards.